Brevan Howard Capital Management’s AbCellera Biologics ABCL Stock Holding History

Brevan Howard Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$124K	Sell	15,772 -3,052	-16%	-$14.9K	﹤0.01%	1970
2026 Q1	$65.7K	Buy	+18,824	New	+$67.7K	﹤0.01%	2067
2025 Q4	–	Sell	-54,355	Closed	-$273K	–	1718
2025 Q3	$273K	Sell	54,355 -11,252	-17%	-$49.6K	﹤0.01%	1610
2025 Q2	$225K	Sell	65,607 -75,718	-54%	-$188K	﹤0.01%	1668
2025 Q1	$315K	Buy	141,325 +57,806	+69%	+$166K	﹤0.01%	851
2024 Q4	$245K	Buy	83,519 +70,633	+548%	+$197K	﹤0.01%	846
2024 Q3	$33.5K	Buy	+12,886	New	+$35.7K	﹤0.01%	1101

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Brevan Howard Capital Management's ABCL Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its AbCellera Biologics (ABCL) stake by 16% in Q2 2026, selling an estimated $14.9K and leaving 15,772 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #1970.

Brevan Howard Capital Management first reported a position in ABCL in Q3 2024 and has held it in 7 quarters since. The position peaked at $315K in Q1 2025. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Brevan Howard Capital Management held 15,772 shares of AbCellera Biologics worth $124K as of Q2 2026.
Brevan Howard Capital Management sold 3,052 AbCellera Biologics shares in Q2 2026, an estimated $14.9K.
AbCellera Biologics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1970 holding.
Brevan Howard Capital Management first reported a position in AbCellera Biologics in Q3 2024 and has held it in 7 quarters since.
Brevan Howard Capital Management's AbCellera Biologics position peaked at $315K in Q1 2025.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.